Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MRAINYSE:UPCNASDAQ:VRAXNASDAQ:WINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRAIMarpai$1.35-6.9%$1.24$0.40▼$1.68$22.32M4.7919,096 shs20,941 shsUPCUniverse Pharmaceuticals$3.65-3.7%$4.52$2.51▼$2,592.00$157K1.51175,631 shs15,224 shsVRAXVirax Biolabs Group$0.78+1.3%$0.97$0.75▼$9.00$2.52M1.771.73 million shs39,145 shsWINTWindtree Therapeutics$0.45-1.4%$0.79$0.36▼$737.44$1.65M0.771.32 million shs1.31 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRAIMarpai0.00%-2.88%+2.20%+32.35%+98.53%UPCUniverse Pharmaceuticals0.00%-7.12%-23.96%-10.98%-99.76%VRAXVirax Biolabs Group0.00%-2.86%-17.89%-31.58%-32.76%WINTWindtree Therapeutics0.00%-21.14%-42.60%-64.33%-99.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMRAIMarpaiN/AN/AN/AN/AN/AN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVRAXVirax Biolabs Group3.6047 of 5 stars3.55.00.00.03.81.70.6WINTWindtree Therapeutics2.1612 of 5 stars3.02.00.00.03.50.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMRAIMarpai 0.00N/AN/AN/AUPCUniverse Pharmaceuticals 0.00N/AN/AN/AVRAXVirax Biolabs Group 3.00Buy$3.00284.62% UpsideWINTWindtree Therapeutics 2.00Hold$350.0077,764.29% UpsideCurrent Analyst Ratings BreakdownLatest MRAI, VRAX, WINT, and UPC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025VRAXVirax Biolabs GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMRAIMarpai$34.87M0.64N/AN/A($1.72) per share-0.78UPCUniverse Pharmaceuticals$23.02M0.01N/AN/A$163.50 per share0.02VRAXVirax Biolabs Group$160K15.75N/AN/A$2.00 per share0.39WINTWindtree TherapeuticsN/AN/AN/AN/A$38.99 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMRAIMarpai-$28.75M-$1.82N/A∞N/A-85.70%N/A-100.23%8/5/2025 (Estimated)UPCUniverse Pharmaceuticals-$6.16MN/A0.00∞N/AN/AN/AN/AN/AVRAXVirax Biolabs Group-$6.73MN/A0.00∞N/AN/AN/AN/AN/AWINTWindtree Therapeutics-$1.79M-$823.47N/AN/AN/AN/A-227.93%-56.46%8/18/2025 (Estimated)Latest MRAI, VRAX, WINT, and UPC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025WINTWindtree Therapeutics-$39.00-$4.63+$34.37-$4.63$2.20 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMRAIMarpaiN/AN/AN/AN/AN/AUPCUniverse PharmaceuticalsN/AN/AN/AN/AN/AVRAXVirax Biolabs GroupN/AN/AN/AN/AN/AWINTWindtree TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMRAIMarpaiN/A0.820.82UPCUniverse PharmaceuticalsN/AN/AN/AVRAXVirax Biolabs GroupN/A11.5711.39WINTWindtree TherapeuticsN/A0.250.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMRAIMarpai49.75%UPCUniverse Pharmaceuticals0.18%VRAXVirax Biolabs Group8.61%WINTWindtree Therapeutics29.33%Insider OwnershipCompanyInsider OwnershipMRAIMarpai61.30%UPCUniverse Pharmaceuticals57.38%VRAXVirax Biolabs Group45.10%WINTWindtree Therapeutics0.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMRAIMarpai15016.53 million5.61 millionNo DataUPCUniverse Pharmaceuticals22043,000731,000Not OptionableVRAXVirax Biolabs Group53.23 million1.78 millionNot OptionableWINTWindtree Therapeutics303.66 million3.65 millionNot OptionableMRAI, VRAX, WINT, and UPC HeadlinesRecent News About These CompaniesWindtree Therapeutics Signs Agreement to Cut PHEXXI Manufacturing Costs by Over 50% Through Partnership with Chinese ManufacturerJune 26, 2025 | quiverquant.comQWindtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive GelJune 26, 2025 | globenewswire.comWindtree Therapeutics Announces Promising Phase 2 Study Results for IstaroximeJune 17, 2025 | msn.comWindtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B StudyJune 16, 2025 | manilatimes.netMWindtree Therapeutics Receives $7 Million Offer for Preclinical Oncology PlatformJune 14, 2025 | msn.comWindtree Therapeutics: Windtree Receives Offer for Its Preclinical Oncology Drug CandidateJune 13, 2025 | finanznachrichten.deWindtree Receives Offer for Its Preclinical Oncology Drug CandidateJune 11, 2025 | tmcnet.comWindtree Therapeutics, Inc. Secures $7 Million Up Front for Preclinical Oncology Drug Candidate, Potentially Worth $130 Million in Milestones and $1.5 Billion in RoyaltiesJune 11, 2025 | quiverquant.comQWorking to clean up its finances, Windtree Therapeutics gets into the garbage businessJune 10, 2025 | bizjournals.comWindtree Announces Transformational Agreement to Acquire Revenue Generating Environmental Services BusinessJune 10, 2025 | tmcnet.comWindtree Therapeutics to acquire Titan Environmental ServicesJune 10, 2025 | msn.comWINT stock touches 52-week low at $0.75 amid steep annual declineMay 24, 2025 | uk.investing.comWindtree Therapeutics Advances Istaroxime Cardiogenic Shock Program with SEISMiC C Study Interim Analysis Planned for July 2025May 22, 2025 | quiverquant.comQWindtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025May 22, 2025 | globenewswire.comWindtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure ConferenceMay 19, 2025 | manilatimes.netMWindtree Therapeutics to Present Istaroxime Data at European Society of Cardiology Heart Failure 2025 ConferenceMay 19, 2025 | quiverquant.comQWindtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business UpdatesMay 16, 2025 | finanznachrichten.deWindtree Therapeutics announces resale of 42.17M shares by selling stockholdersMay 16, 2025 | msn.comWindtree Therapeutics Announces Positive Results on Istaroxime and SERCA2a Activator in Reducing Arrhythmias at ESC Heart Failure CongressMay 13, 2025 | nasdaq.comWindtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025May 12, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRAI, VRAX, WINT, and UPC Company DescriptionsMarpai NASDAQ:MRAI$1.35 -0.10 (-6.90%) As of 06/27/2025 01:54 PM EasternMarpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, bill review and cost containment services. Marpai, Inc. was incorporated in 2021 and is based in Tampa, Florida.Universe Pharmaceuticals NYSE:UPC$3.65 -0.14 (-3.69%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$4.65 +1.00 (+27.40%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.Virax Biolabs Group NASDAQ:VRAX$0.78 +0.01 (+1.30%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$0.81 +0.03 (+3.85%) As of 04:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.Windtree Therapeutics NASDAQ:WINT$0.45 -0.01 (-1.43%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.43 -0.02 (-3.67%) As of 04:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
